Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent hi.

Mahmood ST, Agresta S, Vigil CE, Zhao X, Han G, D'Amato G, Calitri CE, Dean M, Garrett C, Schell MJ, Antonia S, Chiappori A; Int. J. Cancer. 2011-10-15.

Phase II study of sunitinib malate (SM) in subjects with metastatic and/or surgically unresectable non-GIST soft tissue sarcomas.

Vigil CE, Chiappori AA, Williams CA, Shrager HH, Murray BL, Letson DG, Sullivan DM, Garrett CR, D'Amato GZ, Agresta SV; J. Clin. Oncol.. 2008-05-20.

Preliminary efficacy and safety results of glufosfamide (GLU) in relapsed soft tissue sarcoma: Results of a phase II trial.

D'Amato GZ, Verschraegen CF, Cranmer LD, Ganjoo KN, Rosen G, Adkins DR, Mendelson DS, Langmuir VK, Kroll S; J. Clin. Oncol.. 2008-05-20.